15
Views
8
CrossRef citations to date
0
Altmetric
Review

The therapeutic potential of islet cell transplant in the treatment of diabetes

Pages 785-795 | Published online: 23 Feb 2005
 

Abstract

Diabetic patients requiring insulin treatment are at an increased risk of developing chronic complications affecting the eye, kidney and heart as well as other disabilities, such as neurological and vascular disease. The Diabetes Control and Complications Trial (DCCT) showed that the development of these complications can be profoundly reduced or even prevented by strict glycaemic control through intensive insulin therapy. The DCCT study, which was concluded in 1993, administered intensive insulin treatment either by multiple (three or four per day) insulin injections or by an external insulin pump. However, it is both stressful and difficult to achieve effective glycaemic control by these methods. Furthermore, intensive insulin administration imposes a significant danger of hypoglycaemia to patients receiving this treatment. Biological replacement of the destroyed insulin-producing B-cells of pancreatic islets, with normal functioning islet transplants, remains the best option with which to achieve strict glycaemic control in diabetic patients requiring insulin treatment. The ultimate goal in transplantation is the unlimited availability of organs/tissues to be transplanted in a simple procedure that requires little or no immunosuppression. Other obstacles have also contributed to the delay in islet transplantation becoming a clinical reality. There are now good methods for isolating long-term functional islets, and it has been proposed that these islets can be immunoisolated by microencapsulation to prevent transplant rejection, an approach that could easily lead to the use of islet xenografts in human diabetic patients. Therefore, the development of microencapsulated islets promises to solve the two major obstacles to clinical islet transplantation, transplant rejection and shortage of human islets. This technique has enormous potential as a viable treatment for diabetic patients requiring insulin therapy to achieve glycaemic control.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.